Ingenol mebutate (IM) is a topical pharmacotherapy approved in Switzerland since 2012 for treating non-hypertrophic, non-hyperkeratotic actinic keratosis. We report a case with off-label use of IM where Bowen's disease has been successfully treated with physician-directed IM 0.015% gel under occlusion over the chest area.

Keywords:
Ingenol mebutate, Bowen’s disease, Photodynamic therapy
1.
Jaeger AB, Gramkow A, Hjalgrim H, Melbye M, Frisch M: Bowen disease and risk of subsequent malignant neoplasms: a population-based cohort study of 1147 patients. Arch Dermatol 1999;135:790-793.
2.
Bonerandi JJ, Beauvillain C, Caquant L, et al: French Dermatology Recommendations Association (aRED): Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma and precursor lesions. J Eur Acad Dermatol Venereol 2011;25(suppl 5):1-51.
3.
Bargman H, Hochman J: Topical treatment of Bowen's disease with 5-fluorouracil. J Cutan Med Surg 2003;7:101.
4.
Morton C, Horn M, Leman J, et al: Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial. Arch Dermatol 2006;142:729-735.
5.
Cox NH, Eedy DJ, Morton CA: Guidelines for management of Bowen's disease: 2006 update. Br J Dermatol 2007;156:11-21.
6.
Lansbury L, Bath-Hextall F, Perkins W, et al: Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ 2013;347:f6153.
7.
Love WE, Bernhard JD, Bordeaux JS: Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol 2009;145:1431-1438.
8.
Fallen RS, Gooderham M: Ingenol mebutate: an introduction. Skin Therapy Lett 2012;17:1-3.
9.
Freiberger SN, et al: Ingenol mebutate signals via PKC/MEK/ERK in keratinocytes and induces interleukin decoy receptors IL1R2 and IL13RA2. Mol Cancer Ther 2015;14:2132-2142.
10.
Siller G, Rosen R, Freeman M, et al: PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Australas J Dermatol 2010;51:99-105.
11.
Lee, JH, et al: Successful treatment of Bowen's disease with ingenol mebutate 0.05% gel. J Dermatol 2015;42:920-921.
12.
Braun SA, Homey B, Gerber PA: Erfolgreiche Behandlung Eines Morbus Bowen Mit Ingenolmebutat. Hautarzt 2014;65:848-850.
13.
Ramsay JR, Suhrbier A, Aylward JH, Ogbourne S, Cozzi SJ, Poulsen MG, Baumann KC, Welburn P, Redlich GL, Parsons PG: The sap from Euphorbia peplus is effective against human nonmelanoma skin cancers. Br J Dermatol 2011;164:633-636.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.